文献速递血脂与心血管预防

基于FOURIER试验的PCSK9抑制剂成本效果更新评估

Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
PubMed 文献 · JAMA Cardiol · 2017-01-01

本研究基于FOURIER试验结果,构建Markov模型模拟1000例类似FOURIER人群的患者,评估PCSK9抑制剂联合他汀相比单用他汀的成本效果。私人支付方投资回报率为-86%。PCSK9抑制剂年价格需降至5459美元(降幅62%)才能达到每QALY 10万美元的阈值。

要点

  • 私人支付方视角下PCSK9抑制剂投资回报率为-86%。
  • 价格需降62%至每年5459美元才具成本效果。

核心结论

  • 当前价格下PCSK9抑制剂联合他汀成本效果低,需大幅降价才能符合常规标准。

研究设计与样本

  • 基于FOURIER试验人群特征构建理论队列的Markov模型,模拟终身时间跨度。
  • 模型纳入1000例假设患者,事件率、费用等来自现有文献。

主要发现

  • 概率敏感性分析显示在每QALY 10万美元的社会阈值下具有成本效果的概率低于1%。
  • 私人支付方视角下PCSK9抑制剂投资回报率为-86%。

关键数值与推荐

  • 阈值分析显示价格需下降62%至每年5459美元才能达到每QALY 10万美元。

临床怎么用

  • 临床决策需结合药品价格,当前价格下PCSK9抑制剂成本效果不具优势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Preliminary cost-effectiveness analyses of proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) were based on benefits estimated from reductions in low-density lipoprotein cholesterol that occurred in PCSK9i trials with variable results. The recent Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) trial provides better information about the effectiveness of the drug. OBJECTIVE: To use the trial results to determine the cost-effectiveness of a PCSK9i and statin treatment strategy compared with a statin alone strategy. DESIGN, SETTING, AND PARTICIPANTS: We derived observed rates of events, outcomes, cost of care, and health insurance from existing literature for a theoretical cohort of patients designed to resemble the FOURIER PCSK9i trial population and created a Markov model during the time horizon of a full lifetime. MAIN OUTCOMES AND MEASURES: We evaluated the incremental cost-effectiveness ratio from a health system perspective, and the return on investment from a private payer perspective. For both measures, we assumed an annual PCSK9i drug price of $14 300, with a lapse in US patent protection that would reduce the price by 43% in year 12. Costs were reported in 2016 US dollars. RESULTS: This study modeled 1000 hypothetical patients with attributes similar to those of the FOURIER trial cohort. At the current price, the incremental cost-effectiveness ratio of statin plus PCSK9i therapy was $337 729 per quality-adjusted life-year. Our probabilistic sensitivity analysis found that a statin plus PCSK9i strategy had a low probability (<1%) of being cost effective at the commonly accepted societal threshold of $100 000 per quality-adjusted life-year. Furthermore, PCSK9i produced a negative return on investment of 86% for private payers. In our threshold analysis, the price of PCSK9i would need to drop 62%, to $5459 per year, to reach $100 000 per quality-adjusted life year. CONCLUSIONS AND RELEVANCE: At current prices, the addition of PCSK9i to statin therapy is estimated to provide an additional quality-adjusted life year for $337 729 . Significant discounts are necessary to meet conventional cost-effectiveness standards.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Arrieta A, Hong JC, Khera R, et al. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA Cardiol. 2017. PMID: 29049467. doi:10.1001/jamacardio.2017.3655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。